# Pyrls

**Source:** https://geo.sig.ai/brands/pyrls  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Emerging  
**Website:** pyrls.com  
**Last Updated:** 2026-04-14

## Summary

Modern mobile drug reference app for prescribers with dosing, interactions, and patient education; 50K+ healthcare providers from YC-backed competing with Epocrates for clinical decision support.

## Company Overview

Pyrls is a Minneapolis-based healthcare technology company providing a modern medical drug reference app that enables clinicians, pharmacists, and healthcare trainees to prescribe medications, check interactions, and educate patients more effectively — delivering clinical decision support at the point of care through a mobile-first reference tool that competes with Epocrates as the go-to medication reference for healthcare providers. Founded in 2020 and backed by Y Combinator, Pyrls serves 50,000+ healthcare providers and trainees across hundreds of organizations, achieving $500,000 in revenue in 2024 with a 34-person team.

Pyrls' drug reference platform provides the clinical data clinicians need for safe prescribing: dosing guidelines by indication, route, and patient population (pediatric, renal impairment, hepatic impairment); drug interaction checker; contraindications; pregnancy and lactation safety classifications; and patient education materials for medication counseling. The platform is designed for medical residents, pharmacists, nurse practitioners, and physician assistants who need quick access to accurate drug information during clinical workflows.

In 2025, Pyrls competes in the clinical decision support and drug reference app market with Epocrates (athenahealth-owned, the dominant drug reference app for physicians), Medscape Reference (WebMD), Lexicomp (Wolters Kluwer), and Micromedex for clinical drug reference at point of care. Epocrates has long dominated this category through its free-to-use model funded by pharmaceutical advertising (drug promotions to prescribers) — a model that has faced scrutiny from medical ethics perspectives. Pyrls' competitive differentiation includes a modern interface (Epocrates' UI has been criticized as dated), pharmacist-specific features, and a clean direct subscription model without pharmaceutical advertising. The 2025 strategy focuses on growing through medical school and residency program institutional contracts, expanding the clinical content beyond drug reference into broader clinical decision support, and building integrations with EHR systems for seamless reference during documentation.

## Frequently Asked Questions

### What is Pyrls?
Pyrls is a Minneapolis-based healthcare technology company founded in 2020 that provides a modern medical reference app for healthcare providers. The platform enables clinicians to more effectively prescribe medications, dispense treatments, and educate patients on prescriptions, building the future of how clinicians learn and manage clinical practice information.

### What products and services does Pyrls offer?
Pyrls offers a medical reference app with prescription management tools and patient education resources. The platform serves as a comprehensive drug reference solution for healthcare providers to support clinical decision-making and patient care.

### Who is Pyrls designed for?
Pyrls is designed for healthcare providers, including clinicians and medical trainees. The platform currently serves 50,000+ clinicians and trainees across hundreds of healthcare organizations.

### When was Pyrls founded?
Pyrls was founded in 2020 and participated in Y Combinator's Winter 2022 (W22) batch.

### Where is Pyrls located?
Pyrls is based in Minneapolis, Minnesota.

### Has Pyrls raised funding?
Yes, Pyrls has raised pre-seed funding from Y Combinator. The company participated in Y Combinator's Winter 2022 cohort.

### What are Pyrls' key achievements and metrics?
Pyrls achieved $500K in revenue in 2024 with 34 employees and has grown to serve 50,000+ clinicians and trainees across hundreds of organizations. The company has shown consistent revenue growth since its launch in 2020.

### What market does Pyrls operate in?
Pyrls operates in the drug reference app market, which was valued at $4.2 billion in 2024 and is predicted to reach $9.3 billion by 2034, growing at a CAGR of 8.7%. The company competes with established players like Epocrates, Wolters Kluwer, Medscape, and Skyscape.

### How does Pyrls differentiate itself in the market?
Pyrls positions itself as a modern medical reference app focused on building the future of how clinicians learn and manage clinical practice information. The platform emphasizes effective prescription management, dispensing, and patient education tools for healthcare providers.

### What is Pyrls' current growth trajectory?
Pyrls has demonstrated consistent revenue growth since its launch in 2020, reaching $500K in revenue by 2024. The company has expanded to serve 50,000+ clinicians and trainees across hundreds of organizations.

## Tags

healthtech, b2b, b2c, north-america

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*